{"filing":{"accession_number":"0001683168-26-004481","cik":"0001787740","ticker":"VBIO","company_name":"Valion Bio, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"valion_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826004481/valion_8k.htm"},"events":[{"id":7313,"run_id":6421,"accession_number":"0001683168-26-004481","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Valion Bio held its Annual Meeting of Stockholders on May 28, 2026, with shareholders voting on eight proposals including director elections, an amendment to the 2021 Equity Incentive Plan increasing authorized shares by 2,581,608, auditor ratification, and four Nasdaq Rule 5635(d) approvals for dilutive equity issuances to institutional investors and Tumim Stone Capital. All proposals passed.","company_name":"Valion Bio, Inc.","ticker":"VBIO","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":4149,"accession_number":"0001683168-26-004481","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2021 Equity Incentive Plan increasing authorized shares by 2,581,608 shares, effective May 28, 2026. This is a compensatory arrangement amendment affecting equity grants available to officers and directors, fitting the exec_compensation category. The material increase in share authorization would affect investor assessment of dilution and executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:50:47.151536+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4150,"accession_number":"0001683168-26-004481","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Valion Bio's Annual Meeting held on May 28, 2026. The filing presents detailed vote tallies for eight proposals, including director election (Proposal 1), equity plan amendment (Proposal 2), auditor ratification (Proposal 3), and four Nasdaq Rule 5635(d) approvals for dilutive issuances to institutional investors and Tumim Stone Capital (Proposals 4-7). All proposals passed. This is a material event as the shareholder approvals—particularly for the dilutive equity issuances—directly affect existing shareholders' ownership and the company's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:50:47.151536+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4149,"accession_number":"0001683168-26-004481","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2021 Equity Incentive Plan increasing authorized shares by 2,581,608 shares, effective May 28, 2026. This is a compensatory arrangement amendment affecting equity grants available to officers and directors, fitting the exec_compensation category. The material increase in share authorization would affect investor assessment of dilution and executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:50:47.151536+00:00","company_name":"Valion Bio, Inc.","ticker":"VBIO","filing_date":"2026-06-03"},{"id":4150,"accession_number":"0001683168-26-004481","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Valion Bio's Annual Meeting held on May 28, 2026. The filing presents detailed vote tallies for eight proposals, including director election (Proposal 1), equity plan amendment (Proposal 2), auditor ratification (Proposal 3), and four Nasdaq Rule 5635(d) approvals for dilutive issuances to institutional investors and Tumim Stone Capital (Proposals 4-7). All proposals passed. This is a material event as the shareholder approvals—particularly for the dilutive equity issuances—directly affect existing shareholders' ownership and the company's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:50:47.151536+00:00","company_name":"Valion Bio, Inc.","ticker":"VBIO","filing_date":"2026-06-03"}]}